The collaboration with a prestigious institution like MSK for developing cancer diagnostic tests is likely to positively impact Biodesix's product development and commercialization efforts in the oncology sector. This partnership could lead to the development of innovative diagnostic solutions, enhancing Biodesix's market position and potentially leading to increased investor confidence and stock price appreciation in the short term.

Bio-Rad's contribution of its digital PCR assay technology to Biodesix's efforts in developing cancer diagnostic tests represents a strategic collaboration that could enhance Bio-Rad's visibility and reputation in the diagnostics market. This partnership may lead to increased demand for Bio-Rad's technology and products, potentially having a positive impact on its stock price in the short term.